These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 28931534)

  • 1. The yin and yang of fever after meningococcal B vaccination.
    Ladhani SN; Riordan A
    Arch Dis Child; 2017 Oct; 102(10):881-882. PubMed ID: 28931534
    [No Abstract]   [Full Text] [Related]  

  • 2. The introduction of the meningococcal B (MenB) vaccine (Bexsero®) into the national infant immunisation programme--New challenges for public health.
    Ladhani SN; Campbell H; Parikh SR; Saliba V; Borrow R; Ramsay M
    J Infect; 2015 Dec; 71(6):611-4. PubMed ID: 26433141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meningococcal disease: Can we predict the unpredictable?
    Martinón-Torres F; Trilla A
    Med Clin (Barc); 2020 Jan; 154(1):20-22. PubMed ID: 31350058
    [No Abstract]   [Full Text] [Related]  

  • 4. Pfizer’s men B vaccine shows promise in phase 2.
    Hum Vaccin Immunother; 2012 Aug; 8(8):1016-7. PubMed ID: 23359878
    [No Abstract]   [Full Text] [Related]  

  • 5. Short-term safety of 4CMenB vaccine during a mass meningococcal B vaccination campaign in Quebec, Canada.
    De Serres G; Billard MN; Gariépy MC; Rouleau I; Toth E; Landry M; Boulianne N; Gagné H; Gilca V; Deceuninck G; Ouakki M; Skowronski DM
    Vaccine; 2018 Dec; 36(52):8039-8046. PubMed ID: 30467063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First immunogenicity data for the UK serogroup B meningococcal vaccination schedule in infants.
    McNamara LA; Mbaeyi S
    Lancet Infect Dis; 2021 May; 21(5):586-587. PubMed ID: 33428869
    [No Abstract]   [Full Text] [Related]  

  • 7. Emerging experience with meningococcal serogroup B protein vaccines.
    Toneatto D; Pizza M; Masignani V; Rappuoli R
    Expert Rev Vaccines; 2017 May; 16(5):433-451. PubMed ID: 28375029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of serogroup B meningococcal disease.
    Stephens DS
    Lancet; 2012 Feb; 379(9816):592-4. PubMed ID: 22260987
    [No Abstract]   [Full Text] [Related]  

  • 9. A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn?
    Martin NG; Snape MD
    Expert Rev Vaccines; 2013 Aug; 12(8):837-58. PubMed ID: 23984957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reply to: Introducing vaccination against serogroup B meningococcal disease: An economic and mathematical modelling study of potential impact.
    Wassil J; Huels J; Narasimhan V
    Vaccine; 2014 May; 32(25):2943. PubMed ID: 23962533
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: Safety review: Two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease, Nokleby H, Aavitsland P, O'Hallahan J, Feiring B, Tilman S, Oster P. Vaccine 2007;25(16):3080-4.
    Lennon D
    Vaccine; 2007 Sep; 25(39-40):6833; author reply 6833-4. PubMed ID: 17630051
    [No Abstract]   [Full Text] [Related]  

  • 12. New frontiers in meningococcal vaccines.
    Anderson AS; Jansen KU; Eiden J
    Expert Rev Vaccines; 2011 May; 10(5):617-34. PubMed ID: 21604983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meningococcal B immunisation in New Zealand: why haven't we seen the data?
    Bolland M
    N Z Med J; 2008 Mar; 121(1270):107-9. PubMed ID: 18364764
    [No Abstract]   [Full Text] [Related]  

  • 14. Estimating primary care attendance rates for fever in infants after meningococcal B vaccination in England using national syndromic surveillance data.
    Harcourt S; Morbey RA; Bates C; Carter H; Ladhani SN; de Lusignan S; Smith GE; Elliot AJ
    Vaccine; 2018 Jan; 36(4):565-571. PubMed ID: 29246475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease.
    Nøkleby H; Aavitsland P; O'Hallahan J; Feiring B; Tilman S; Oster P
    Vaccine; 2007 Apr; 25(16):3080-4. PubMed ID: 17287053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emergency department attendance following 4-component meningococcal B vaccination in infants.
    Kapur S; Bourke T; Maney JA; Moriarty P
    Arch Dis Child; 2017 Oct; 102(10):899-902. PubMed ID: 28637642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of group B meningococcal disease by vaccination: a difficult task.
    Thomas M
    N Z Med J; 2004 Aug; 117(1200):U1016. PubMed ID: 15475986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Group B meningococcal vaccine science and policy.
    Drysdale SB; Pollard AJ
    J Infect; 2015 Jun; 71 Suppl 1():S15-20. PubMed ID: 25917798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccines for the prevention of meningococcal capsular group B disease: What have we recently learned?
    Findlow J
    Hum Vaccin Immunother; 2016; 12(1):235-8. PubMed ID: 26619037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Meningococcal infections. Every case a preventable tragedy].
    Bischoff A
    MMW Fortschr Med; 2008 Jun; 150(24):17. PubMed ID: 18605054
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.